Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture

W. Lyles, Kenneth; Colón‐Emeric, Cathleen; Magaziner, Jay; D. Adachi, Jonathan; F. Pieper, Carl; Mautalén, C.; Hyldstrup, Lars; Recknor, Chris; Nordsletten, Lars; Moore, K.; Lavecchia, Catherine; Zhang, Jie; Mesenbrink, Peter; Hodgson, Patricia; Abrams, Kenneth; J. Orloff, John; D. Horowitz, Zebulun; Fink Eriksen, Erik; Boonen, Steven

doi:10.1056/nejmoa074941

Public

Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture

Published in New England Journal of Medicine • Sep 18, 2007

Authors:

Kenneth W. Lyles

Cathleen Colón‐Emeric

Jay Magaziner

Abstract

BACKGROUND: Mortality is increased after a hip fracture, and strategies that improve outcomes are needed. METHODS: In this randomized, double-blind, placebo-controlled trial, 1065 patients were assigned to receive yearly intravenous zoledronic acid (at a dose of 5 mg), and 1062 patients were assigne...

Subject

Zoledronic acid

Medicine

Placebo

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!